Name | Title | Contact Details |
---|
Manufacturer of diagnostics for global fungal diseases such as, cryptococcosis, aspergillosis, histoplasmosis, coccidioidomycosis (Valley Fever), blastomycosis, and candida.
CordenPharma is a Boulder, CO-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Vitae Pharmaceuticals, Inc. focuses on discovering and developing drugs for various diseases. Its product candidates include VTP-34072, which is in a Phase II clinical trial for the treatment of type 2 diabetes; and VTP-37948 that is in Phase I clinical trials for alzheimer's disease. The company’s products in preclinical studies comprise VTP-43742 for the treatment of autoimmune disorders, such as psoriasis, multiple sclerosis, rheumatoid arthritis, Behcet's disease, and autoimmune uveitis; VTP-38443 for the treatment of acute coronary syndrome that consists of unstable angina and heart attacks; and VTP-38543 for the treatment of atopic dermatitis, an immune system mediated inflammation of the skin. Vitae Pharmaceuticals, Inc. has collaborations with Boehringer Ingelheim GmbH for the development of VTP-34072 and VTP-37948. Vitae Pharmaceuticals, Inc. was formerly known as Concurrent Pharmaceuticals, Inc. and changed its name to Vitae Pharmaceuticals, Inc. in January, 2005. The company was founded in 2001 and is headquartered in Fort Washington, Pennsylvania.
Kailos Genetics, the maker of Praxis, provides consumers access to affordable physician-ordered genetic tests. It is our mission to help people take control of their health and make more informed decisions through identifying risks to common medications. Praxis is an easily accessible form of personalized medicine catered to your lifestyle.
Atreca is a biotechnology company that develops novel therapeutics through a deep understanding of the human immune response, with a focus on innovative novel cancer immunotherapeutics. With its Immune Repertoire Capture™ (IRC™) technology, Atreca has an unparalleled insight into how cancer patients` immune responses can drive better clinical outcomes. Atreca was founded by scientists, industry experts, and investors who share the vision that unlocking the immune response of today`s patients is the key to creating a new generation of therapies. Atreca is looking for talented, entrepreneurial people who are dedicated to making a positive impact on human health.